Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue (FODMAPS)
Primary Purpose
Irritable Bowel Syndrome
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Low- FODMAPdiet group intervention
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring Low FODMAPdiet
Eligibility Criteria
Inclusion criteria:
- Established IBS-D by RomeIV- criteria
- Established IBS-M by RomeIV- criteria
- Body Mass Index (BMI)18-35
Exclusion criteria:
- Pregnancy
- Lactation
- Ongoing eating disorder/ contact with eating disorder unit
- Postoperative gastrointestinal surgery that may impact on the gastrointestinal function
- Celiac disease
- Psychiatric disorder
- Other disorder that may impact the possibility to participate in group treatment
- Diabetes
- Ongoing low- FODMAPdiet treatment.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Low-FODMAPdiet group
Delayed start of treatment low-FODMAPdiet group
Arm Description
Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.
Delayed start of treatment. This arm starts after three months
Outcomes
Primary Outcome Measures
Change in IBS Symptom Severity Scores (IBS-SSS)
Visual Analogues Scale (VAS-scale), composite score measuring bloating, bowel habits, satisfaction with with bowel habits and how IBS impact on QOL. Minimum score 0 and maximum score 500, higher scores indicates more severe disease
Secondary Outcome Measures
Change in Multidimensional Fatigue Inventory (MFI-20)
The Multidimensional Fatigue Inventory-20 (MFI-20) assesses 5 dimensions of fatigue, the severity of general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Each dimension contain 4 questions. In total 20 questions. Minimum score 0 and maximum score 100. A higher score indicate more severe fatigue.
Change in the gastrointestinal symptom rating scale (GSRS-IBS)
Measuring gastrointestinal symptom severity. Contains 13 questions. Minimum score 13 and maximum score 91. Higher score indicate more severe gastrointestinal symptoms.
Change in Visceral sensitivity index (VSI)
The VSI questionnaire measures GI-specific anxiety, and it includes the cognitive, affective, and behavioral response to fear of GI symptoms, and the context in which these occurs. The questionnaire contains 15 questions. Minimum score 0 and maximum score 75. A higher score indicates a more severe gastrointestinal anxiety.
Change in Sickness behaviour (SQ)
Measuring symptoms that occur after acute or chronic inflammation/ infection ie. malaise, listlessness, inability to concentrate, depressed mood and lack of interest in food and surroundings. The form contains 10 questions. Minimum score 0 and maximum score 30. Higher score indicates more severe sickness behaviour.
Change in World Health Organisation (WHO) Disability Assessment Schedule (WHODAS 2.0)
Measuring difficulties due to state of health. 12 questions. Minimum score is 12 and maximum score is 48. Higher score indicates more severe difficulties due to state.
Full Information
NCT ID
NCT05124262
First Posted
October 26, 2021
Last Updated
July 6, 2022
Sponsor
Karolinska Institutet
Collaborators
Aleris Gastromottagningen City
1. Study Identification
Unique Protocol Identification Number
NCT05124262
Brief Title
Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue
Acronym
FODMAPS
Official Title
Effect of a Low- Fermentable-Oligo-Di-Monosaccharides and Polyols (FODMAPs) Diet Group Intervention on IBS Symptoms and Fatigue
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2023 (Anticipated)
Primary Completion Date
March 15, 2024 (Anticipated)
Study Completion Date
March 15, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
Collaborators
Aleris Gastromottagningen City
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Irritable bowel disease (IBS) is a functional gastrointestinal disorder that affects 10% of the population. Comorbidities are common and fatigue is the most common extraintestinal complaint in IBS patients. There are no cure for the disease but there are nutrition treatments that can relieve symptoms. The main goal of this randomized controlled trial is to test the hypothesis that low-Fermentable- oligo-di- monosaccharides and polyols (FODMAPs) diet kan decrease gastrointestinal symptoms and improve quality of life and fatigue in patients with IBS.
Detailed Description
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by stomach pain at least one day a week accompanied by change in stool frequency or appearance. Prevalence of IBS is about 10 % of the population worldwide and more common in women. IBS is divided into different subclasses: diarrhea predominant, (IBS-D), predominant constipation, (IBS-C), mixed bowel habits, (IBS-M). Comorbidities are common and fatigue is the most common extraintestinal complaint among the patients. Patients has severely reduced quality of life, reduced work capacity and the cost are substantial for the patients and the society. IBS can´t be cured but the symptoms can be relieved by pharmacological as well as non-pharmacological treatment as psychological- and nutritional treatment. The main goal of this randomized controlled trial is to test the hypothesis that low FODMAPdiet kan decrease gastrointestinal symptoms and improve quality of life and fatigue in patients with IBS.
FODMAPs is an acronym for Fermentable-Oligo-Di-Monosaccharides and Polyols. FODMAPs are carbohydrates that can't be absorbed/splinted in the large intestine and they ferment rapidly and exacerbate gastrointestinal symptoms as flatulence, pain, bloating and loose stools. In total 120 patients with IBS-D and IBS-M will be randomized to immediate treatment start or delayed treatment start. The treatment will be performed in clinical setting, led by a dietitian and in group format including 12 patients in each group. The intervention time is 12 weeks with 5 group visits at a gastroenterology unit. The low-FODMAP treatment is divided into three steps: elimination of FODMAPs, re-introduction and personalization of the diet. Compliance to the diet will be measured by monitoring the FODMAP intake from three day food diaries and a compliance form. Questionnaires will be self reported in a web based application. Food diaries and the stomach diary will be filled out at baseline, at week 5, 12 and 6, 12 and 24 months post intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
Keywords
Low FODMAPdiet
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Randomized controlled trial with direct or delayed treatment start
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Low-FODMAPdiet group
Arm Type
Experimental
Arm Description
Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.
Arm Title
Delayed start of treatment low-FODMAPdiet group
Arm Type
Experimental
Arm Description
Delayed start of treatment. This arm starts after three months
Intervention Type
Other
Intervention Name(s)
Low- FODMAPdiet group intervention
Intervention Description
Diet intervention
Primary Outcome Measure Information:
Title
Change in IBS Symptom Severity Scores (IBS-SSS)
Description
Visual Analogues Scale (VAS-scale), composite score measuring bloating, bowel habits, satisfaction with with bowel habits and how IBS impact on QOL. Minimum score 0 and maximum score 500, higher scores indicates more severe disease
Time Frame
Change in baseline week 0 and after elimination at week 5, after intervention at week 12, at week 38 and at 1 year and 3 months and 2 years and three months. Within each patient.
Secondary Outcome Measure Information:
Title
Change in Multidimensional Fatigue Inventory (MFI-20)
Description
The Multidimensional Fatigue Inventory-20 (MFI-20) assesses 5 dimensions of fatigue, the severity of general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Each dimension contain 4 questions. In total 20 questions. Minimum score 0 and maximum score 100. A higher score indicate more severe fatigue.
Time Frame
Between baseline week 0 and after elimination at week 5, after intervention at week 12, at week 38 and at 1 year and 3 months and at 2 years and three months. Within each patient.
Title
Change in the gastrointestinal symptom rating scale (GSRS-IBS)
Description
Measuring gastrointestinal symptom severity. Contains 13 questions. Minimum score 13 and maximum score 91. Higher score indicate more severe gastrointestinal symptoms.
Time Frame
Between baseline week 0 and after elimination at week 5, after intervention at week 12, at week 38 and at 1 year and 3 months and at 2 years and three months. Within each patient.
Title
Change in Visceral sensitivity index (VSI)
Description
The VSI questionnaire measures GI-specific anxiety, and it includes the cognitive, affective, and behavioral response to fear of GI symptoms, and the context in which these occurs. The questionnaire contains 15 questions. Minimum score 0 and maximum score 75. A higher score indicates a more severe gastrointestinal anxiety.
Time Frame
Baseline week 0 and after intervention at 12 weeks and at week 38 and at 1 year and 3 months and 2 years and three months. Within each patient.
Title
Change in Sickness behaviour (SQ)
Description
Measuring symptoms that occur after acute or chronic inflammation/ infection ie. malaise, listlessness, inability to concentrate, depressed mood and lack of interest in food and surroundings. The form contains 10 questions. Minimum score 0 and maximum score 30. Higher score indicates more severe sickness behaviour.
Time Frame
Baseline week 0 after intervention at 12 weeks and at week 38, at 1 year and 3 months and 2 years and three months. Within each patient.
Title
Change in World Health Organisation (WHO) Disability Assessment Schedule (WHODAS 2.0)
Description
Measuring difficulties due to state of health. 12 questions. Minimum score is 12 and maximum score is 48. Higher score indicates more severe difficulties due to state.
Time Frame
Baseline week 0 and at 12 weeks and at week 38, at 1 year and 3 months and 2 years and three months. Within each patient.
Other Pre-specified Outcome Measures:
Title
Change in three day food diary measuring FODMAPintake for compliance to diet intervention
Description
Patient report food intake during three days. Two weekdays and one saturday or sunday.
Time Frame
Baseline week 0, after intervention at 12 weeks and at 38 weeks, at 1 year and three months at 2 years and three months.. Within each patient.
Title
Change in meal pattern stomach diary 7 days,
Description
Measuring meal pattern
Time Frame
Baseline week 0, after intervention at 12 weeks and at 38 weeks, at 1 year and three months and at 2 years and three months. Within each patient.
Title
Change in stool pattern stomach diary 7 days
Description
Measuring stool pattern
Time Frame
Baseline week 0, after intervention at 12 weeks and at 38 weeks, at 1 year and three months and at 2 years and three months. Within each patient.
Title
Change in compliance to FODMAP intervention and level of introduction of FODMAPs
Description
Patients selfreport if they have reintroduced the different FODMAPs ie. fructose, lactose, fructan, galactooligosaccharides and polyols.
Time Frame
Postintervention at 12 weeks and at 38 weeks, 1 year and three months and at 2 years and three months. Within each patient.
Title
Change in Generalized Anxiety disorder (GAD-7)
Description
Measuring anxiety in total 7 questions added with questions about how the anxiety impacts your life. Minimum score 7 and maximum score 28. Higher score indicate more severe anxiety.
Time Frame
Baseline week 0 and after 1 year and three months. Within each patient.
Title
Change in Patients Health questionnaire (PHQ-9)
Description
Screening for depressive symptoms. 9 questions. Minimum score 0 and maximum score 27.
Time Frame
Baseline week 0 and at 1 year and three months. Within each patient.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Established IBS-D by RomeIV- criteria
Established IBS-M by RomeIV- criteria
Body Mass Index (BMI)18-35
Exclusion criteria:
Pregnancy
Lactation
Ongoing eating disorder/ contact with eating disorder unit
Postoperative gastrointestinal surgery that may impact on the gastrointestinal function
Celiac disease
Psychiatric disorder
Other disorder that may impact the possibility to participate in group treatment
Diabetes
Ongoing low- FODMAPdiet treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
PerJohan Lindfors, MD, Med. dr
Phone
08-128 570 00
Email
perjohan.lindfors@ki.se
First Name & Middle Initial & Last Name or Official Title & Degree
Therese Liljebo, PHD- student
Phone
08-128 570 00
Email
therese.liljebo@ki.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
PerJohan Lindfors, MD, Med. dr
Organizational Affiliation
Karolinska Institutet
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue
We'll reach out to this number within 24 hrs